02611nas a2200433   4500000000100000008004100001100002100042700001700063700001700080700001400097700001900111700001700130700002100147700001800168700001500186700001700201700002000218700002000238700001800258700002200276700001900298700001900317700001400336700002100350700001600371700001800387700001800405700002100423700002100444700001800465700002000483700004900503700001900552245010000571300001400671490000800685520147000693022001402163       2017                            d1 aTonelli Marcello1 aCoresh Josef1 aLevin Adeera1 aJardine M1 aGansevoort Ron1 aLevey Andrew1 aBonventre Joseph1 aDonner Jo-Ann1 aFogo Agnes1 aFox Caroline1 aHeerspink Hiddo1 aKasiske Bertram1 aKöttgen Anna1 aKretzler Matthias1 aLuyckx Valerie1 aMehta Ravindra1 aMoe Orson1 aObrador Gregorio1 aPannu Neesh1 aParikh Chirag1 aPollock Carol1 aStenvinkel Peter1 aTuttle Katherine1 aWheeler David1 aEckardt Kai-Uwe1 aISN Global Kidney Health Summit participants1 aPerkovic Vlado00aGlobal kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy.  a1888-19170 v3903 a<p>The global nephrology community recognises the need for a cohesive plan to address the problem of chronic kidney disease (CKD). In July, 2016, the International Society of Nephrology hosted a CKD summit of more than 85 people with diverse expertise and professional backgrounds from around the globe. The purpose was to identify and prioritise key activities for the next 5-10 years in the domains of clinical care, research, and advocacy and to create an action plan and performance framework based on ten themes: strengthen CKD surveillance; tackle major risk factors for CKD; reduce acute kidney injury-a special risk factor for CKD; enhance understanding of the genetic causes of CKD; establish better diagnostic methods in CKD; improve understanding of the natural course of CKD; assess and implement established treatment options in patients with CKD; improve management of symptoms and complications of CKD; develop novel therapeutic interventions to slow CKD progression and reduce CKD complications; and increase the quantity and quality of clinical trials in CKD. Each group produced a prioritised list of goals, activities, and a set of key deliverable objectives for each of the themes. The intended users of this action plan are clinicians, patients, scientists, industry partners, governments, and advocacy organisations. Implementation of this integrated comprehensive plan will benefit people who are at risk for or affected by CKD worldwide.</p>  a1474-547X